Thursday 27 February 2020

Vaxil Bio: A Coronavirus Stock On The TSX Venture

Fears of Coronavirus spreading have wreaked havoc on the markets this week. There have been a handful of stocks on the move up that hope to find a vaccine or are otherwise plays on containing the outbreak such as Coronavirus tests and mask companies. Stocks like Alpha Pro Tech (APT), Vaxart (VXRT), iBio (IBIO), NanoViricides (NNVC) and Co-Diagnostics (CODX), among others have all been trading upwards. Vaxil Bio (VXL.V) (VXLLF) is a Canadian microcap working on a Coronavirus vaccine that should see a huge move up. It is trailing the others since it is a relatively unknown penny stock but we think that could change as traders scour the market for good deals.We are up to 869 followers on our ValueTrades blog despite not giving out a lot of alerts, a fact that we think is indicative of a successful, diligent and prudent stock picking history. You can follow us on Twitter @StockTradePicks. We have over 4,000 followers on Twitter.

VXL is up 33% so far today on over a million shares traded but could go a lot higher at is has only a $7 million market cap at $0.08. It shot up as high at $0.195 on February 18 versus $0.025 a few days earlier on the announcement of successfully identifying a Coronavirus vaccine candidate:

NESS-ZIONA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has completed in silico analyses and believes that it has successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform. The Vaccine Candidate’s design is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine.
“We are very excited to have been able to isolate a preliminary candidate that might address the current and emerging need in such a short time,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, who went on to say that “we look forward to the next step of identifying resources and partners to solidify the most efficient path forward.”
Mr. Goren continued to explain that “we have identified signal peptide combinations which we believe can be effective as a prophylactic vaccine against the current corona virus and might also demonstrate therapeutic value in the future.”
Vaxil plans to initiate non-GMP manufacturing followed by testing as we explore partnerships and other possibilities.

NESS-ZIONA, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide further update to the Company’s press release dated February 13, 2020 on the possible identification of a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”).
The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHitTM bioinformatics platform. The Vaccine Candidate’s design is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine.  Though significant, this is an early step in identifying a vaccine candidate which must then go through rigorous testing before approval by regulatory authorities.
During the next quarter, Vaxil plans to initiate non-GMP manufacturing. The non-GMP product will be made available for pre-clinical testing by those who express interest and qualify. In addition, Vaxil will explore partnerships and other possibilities to test the vaccine and if successful to bring to patients worldwide as expeditiously as possible
“This is a very early discovery and it is unlikely that there will be a prophylactic vaccine during this season, but we endeavor to have one for future use.” said David Goren, Vaxil’s Chairman and Chief Executive Officer.
While VXL is at a very early stage, it also has by far the cheapest market cap of all Coronavirus stocks. We expect this one to fly as it has remained relatively under the radar.

Disclosure: We are long VXL.V


What's next for microcap stocks? TradeMiner identifies seasonal trends and market cycles, the Penny Stock Prophet and Microcap Millionaires finds the next big small cap plays in various industries while Addicted to Profits makes trades from a Canadian perspective.

There are also some good books available on microcap stocks and day trading such as:

Mastering Microcaps: Strategies, Trends, and Stock Selection (Bloomberg Professional Library)

The Little Black Book of Microcap Investing: Beat the Market with NASDAQ/AMEX Microcap Stocks, OTCBB Penny Stocks, and Pink Sheet Stocks

Microcap Magic: Why The Biggest Returns Are In Stocks You've Never Heard Of

How to Day Trade for a Living: A Beginner’s Guide to Trading Tools and Tactics, Money Management, Discipline and Trading Psychology

How to Day Trade: A Detailed Guide to Day Trading Strategies, Risk Management, and Trader Psychology

A Beginner's Guide to Day Trading Online (2nd edition)

Stock Investing for Beginners: Marijuana Stocks


Here are some other good stock market resources. This includes technical analysis and day trading, dividend stock investing, gold and commodities, sector rotation, options trading and microcap trading strategies:

The dividend stock report from dividendstocksonline.com

Posted by at